Barclays’s Jazz Pharmaceuticals JAZZ Stock Holding History

Barclays’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-158,700	Closed	-$27M	–	5247
2025 Q4	$27M	Buy	158,700 +93,200	+142%	+$14.3M	0.01%	1076
2025 Q3	$8.63M	Buy	+65,500	New	+$7.86M	﹤0.01%	1783
2021 Q3	–	Sell	-37,500	Closed	-$6.66M	–	4883
2021 Q2	$6.66M	Buy	+37,500	New	+$6.5M	﹤0.01%	1418
2019 Q1	–	Sell	-2,700	Closed	-$335K	–	7166
2018 Q4	$335K	Hold	2,700	–	–	﹤0.01%	4184
2018 Q3	$454K	Sell	2,700 -12,500	-82%	-$2.15M	﹤0.01%	4350
2018 Q2	$2.62M	Buy	+15,200	New	+$2.48M	﹤0.01%	2311
2017 Q2	–	Sell	-1,600	Closed	-$232K	–	6782
2017 Q1	$232K	Hold	1,600	–	–	﹤0.01%	4164
2016 Q4	$174K	Buy	+1,600	New	+$178K	﹤0.01%	4317
2014 Q4	–	Sell	-10,000	Closed	-$1.6M	–	7432
2014 Q3	$1.6M	Buy	+10,000	New	+$1.54M	﹤0.01%	2882

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Barclays's JAZZ Position: Q2 2026 in Review

Barclays reduced its Jazz Pharmaceuticals (JAZZ) stake by 38% in Q2 2026, selling an estimated $2.26M and leaving 16,494 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Barclays first reported a position in JAZZ in Q2 2013 and has held it in 52 quarters since. The position peaked at $19.7M in Q4 2016. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

Barclays held 16,494 shares of Jazz Pharmaceuticals worth $3.97M as of Q2 2026.
Barclays sold 10,314 Jazz Pharmaceuticals shares in Q2 2026, an estimated $2.26M.
Jazz Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1961 holding.
Barclays first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Barclays's Jazz Pharmaceuticals position peaked at $19.7M in Q4 2016.
646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.